CHINA PHARMA HOLDINGS INC (CPHI) Stock Fundamental Analysis

NYSEARCA:CPHI • US16941T4013

0.6477 USD
+0.02 (+2.81%)
Last: Feb 18, 2026, 08:22 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

CPHI gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. CPHI has a bad profitability rating. Also its financial health evaluation is rather negative. CPHI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year CPHI has reported negative net income.
  • In the past year CPHI had a positive cash flow from operations.
  • In the past 5 years CPHI always reported negative net income.
  • In the past 5 years CPHI always reported negative operating cash flow.
CPHI Yearly Net Income VS EBIT VS OCF VS FCFCPHI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M -20M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -26.56%, CPHI is in line with its industry, outperforming 56.54% of the companies in the same industry.
  • CPHI's Return On Equity of -56.58% is in line compared to the rest of the industry. CPHI outperforms 48.17% of its industry peers.
Industry RankSector Rank
ROA -26.56%
ROE -56.58%
ROIC N/A
ROA(3y)-24.28%
ROA(5y)-20.29%
ROE(3y)-65.01%
ROE(5y)-57.47%
ROIC(3y)N/A
ROIC(5y)N/A
CPHI Yearly ROA, ROE, ROICCPHI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CPHI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CPHI Yearly Profit, Operating, Gross MarginsCPHI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • CPHI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CPHI has more shares outstanding
  • Compared to 5 years ago, CPHI has more shares outstanding
  • The debt/assets ratio for CPHI is higher compared to a year ago.
CPHI Yearly Shares OutstandingCPHI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
CPHI Yearly Total Debt VS Total AssetsCPHI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • CPHI has an Altman-Z score of -5.14. This is a bad value and indicates that CPHI is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of CPHI (-5.14) is worse than 63.35% of its industry peers.
  • CPHI has a debt to FCF ratio of 48.73. This is a negative value and a sign of low solvency as CPHI would need 48.73 years to pay back of all of its debts.
  • CPHI's Debt to FCF ratio of 48.73 is fine compared to the rest of the industry. CPHI outperforms 74.87% of its industry peers.
  • A Debt/Equity ratio of 0.53 indicates that CPHI is somewhat dependend on debt financing.
  • CPHI has a Debt to Equity ratio of 0.53. This is in the lower half of the industry: CPHI underperforms 63.35% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.53
Debt/FCF 48.73
Altman-Z -5.14
ROIC/WACCN/A
WACC7.04%
CPHI Yearly LT Debt VS Equity VS FCFCPHI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M 40M 50M

2.3 Liquidity

  • CPHI has a Current Ratio of 0.51. This is a bad value and indicates that CPHI is not financially healthy enough and could expect problems in meeting its short term obligations.
  • CPHI has a worse Current ratio (0.51) than 92.67% of its industry peers.
  • CPHI has a Quick Ratio of 0.51. This is a bad value and indicates that CPHI is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of CPHI (0.19) is worse than 93.72% of its industry peers.
Industry RankSector Rank
Current Ratio 0.51
Quick Ratio 0.19
CPHI Yearly Current Assets VS Current LiabilitesCPHI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • CPHI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 74.70%, which is quite impressive.
  • Looking at the last year, CPHI shows a very negative growth in Revenue. The Revenue has decreased by -29.64% in the last year.
  • Measured over the past years, CPHI shows a very negative growth in Revenue. The Revenue has been decreasing by -16.15% on average per year.
EPS 1Y (TTM)74.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.84%
Revenue 1Y (TTM)-29.64%
Revenue growth 3Y-22.27%
Revenue growth 5Y-16.15%
Sales Q2Q%10.91%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CPHI Yearly Revenue VS EstimatesCPHI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • CPHI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CPHI Price Earnings VS Forward Price EarningsCPHI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, CPHI is valued a bit cheaper than 78.01% of the companies in the same industry.
Industry RankSector Rank
P/FCF 46.25
EV/EBITDA N/A
CPHI Per share dataCPHI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • CPHI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CHINA PHARMA HOLDINGS INC

NYSEARCA:CPHI (2/18/2026, 8:22:55 PM)

0.6477

+0.02 (+2.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-25
Earnings (Next)N/A
Inst Owners1.2%
Inst Owner Change-0.99%
Ins Owners53.39%
Ins Owner Change0%
Market Cap3.25M
Revenue(TTM)4.40M
Net Income(TTM)-3.66M
Analysts0
Price TargetN/A
Short Float %1%
Short Ratio0.35
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.74
P/FCF 46.25
P/OCF 7.65
P/B 0.5
P/tB 148.47
EV/EBITDA N/A
EPS(TTM)-1.58
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.01
FCFY2.16%
OCF(TTM)0.08
OCFY13.06%
SpS0.88
BVpS1.29
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -26.56%
ROE -56.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 1.6%
ROA(3y)-24.28%
ROA(5y)-20.29%
ROE(3y)-65.01%
ROE(5y)-57.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.53
Debt/FCF 48.73
Debt/EBITDA N/A
Cap/Depr 19.75%
Cap/Sales 8.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.51
Quick Ratio 0.19
Altman-Z -5.14
F-Score5
WACC7.04%
ROIC/WACCN/A
Cap/Depr(3y)8.82%
Cap/Depr(5y)14.6%
Cap/Sales(3y)3.86%
Cap/Sales(5y)4.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.84%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-29.64%
Revenue growth 3Y-22.27%
Revenue growth 5Y-16.15%
Sales Q2Q%10.91%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y106.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y148.16%
OCF growth 3YN/A
OCF growth 5YN/A

CHINA PHARMA HOLDINGS INC / CPHI FAQ

Can you provide the ChartMill fundamental rating for CHINA PHARMA HOLDINGS INC?

ChartMill assigns a fundamental rating of 1 / 10 to CPHI.


What is the valuation status of CHINA PHARMA HOLDINGS INC (CPHI) stock?

ChartMill assigns a valuation rating of 1 / 10 to CHINA PHARMA HOLDINGS INC (CPHI). This can be considered as Overvalued.


What is the profitability of CPHI stock?

CHINA PHARMA HOLDINGS INC (CPHI) has a profitability rating of 1 / 10.